Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination with a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)

C Buddy Creech,1 Robert W Frenck Jr,2 Anne Fiquet,3 Robert Feldman,4 Martin K Kankam,5 Sudam Pathirana,6 James Baber,7 David Radley,6 David Cooper,6 Joseph Eiden,6 William C Gruber,6 Kathrin U Jansen,6 Annalisa S Anderson,6 and Alejandra Gurtman;6 on behalf of the B3451014 Study Group

1Vanderbilt University School of Medicine and the Monroe Carell Jr. Children’s Hospital, Nashville, Tennessee; 2Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 3Pfizer Vaccines Research & Development, Hurley, Berkshire, UK; 4QPS-MRA, Miami Research Associates LLC, Miami, Florida; 5Vince and Associates Clinical Research, Overland Park, Kansas; 6Pfizer Vaccines Research & Development, Pearl River, New York; 7Pfizer Vaccines Research & Development, Sydney, New South Wales, Australia

ClinicalTrials.gov: NCT01643941 and NCT01364571

Correspondence: C. Buddy Creech, Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, S-2323 MCN, 1161 21st Avenue South, Nashville, TN 37232 (buddy.creech@vanderbilt.edu).
Telephone: +1 615-343-0332, Fax: +1 615-343-4738

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
**Correspondence** (alternate corresponding author): Robert W Frenck Jr, University of Cincinnati School of Medicine and Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229. (Robert.Frenck@cchmc.org). Telephone: +1 513-636-4463.

**Author contributions**

All authors participated in the interpretation of study results, and in the drafting, critical revision, and approval of the final version of the manuscript. DC, JB, JE, WCG, SP, ASA, and KUJ were involved in the study design. CBC, RWF, SP, and DC collected the data. CBC, AF, RWF, MKK, SP, JB, DR, DC, JE, WCG, ASA, and KUJ interpreted the results. CBC, RWF and MKK were investigators in the study. AF and DR conducted the statistical analysis.

**Keywords** (5 maximum). *Staphylococcus aureus*; vaccine; vaccine immunogenicity persistence; SA4Ag; orthopedic infections

**Key points** (40 words maximum)

An investigational *Staphylococcus aureus* 4-antigen vaccine (SA4Ag) designed to prevent post-operative invasive orthopedic infections was well tolerated and induced functional immune responses that were durable through 36 months after vaccination.
Abstract (250 words maximum)

**Background.** *Staphylococcus aureus* (*S. aureus*) causes serious healthcare- and community-associated disease, requiring improved preventive measures such as vaccines. The investigational *S. aureus* 4-antigen vaccine (SA4Ag), comprising capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) conjugated to CRM<sub>197</sub>, recombinant mutant clumping factor A (rmClfA), and recombinant manganese transporter protein C (rP305A or rMntC), was well tolerated, inducing robust functional immune responses to all 4 antigens through 12 months post-vaccination. This is a serological extension study through 36 months post-vaccination.

**Methods.** In 2 previous studies, healthy adults received SA4Ag, SA3Ag (without rMntC), or placebo; serology was also assessed at ~24- and ~36-months post-vaccination. Functional immune responses (antibody responses that facilitate killing of *S. aureus* or neutralize *S. aureus* virulence mechanisms) were assessed with opsonophagocytic activity killing assays (CP5 or CP8) and a fibrinogen-binding inhibition assay (ClfA). A competitive Luminex<sup>®</sup> immunoassay assessed ClfA and rMntC responses. Adverse events within 48 hours of blood draw were recorded.

**Results.** 440 subjects (18–64 years-old:255; 65–85 years-old:185) were enrolled. At 24- and 36-months post-vaccination, subjects receiving SA4Ag had substantially higher geometric mean titers (GMTs) for CP5, CP8, and ClfA, versus baseline; geometric mean fold rises (GMFRs) from baseline to month 36 were 2.7–8.1. For rMntC, 36-month GMTs declined from peak levels, but remained above baseline for all SA4Ag groups; GMFRs from baseline to month 36 were 1.8 and 1.5 in the younger and older cohorts, respectively.

**Conclusions.** Persistent functional immune responses to *S. aureus* antigens were observed through 36 months in healthy adults.
INTRODUCTION

*Staphylococcus aureus* (*S. aureus*) is a major cause of healthcare-associated infections, including bacteremia, lower respiratory infection, skin and soft tissue infections, and surgical-site infections \(^1-^3\). Patients with *S. aureus* infections (either methicillin-sensitive or methicillin-resistant) experience worse outcomes than uninfected patients, as measured by length of hospital stay, cost of care/hospital charges, and hospital mortality \(^4\).

Improved measures are urgently needed to prevent *S. aureus* infection, including vaccines \(^5\), especially as antibiotic drug resistance has led to fewer treatment options and generally more complex treatment regimens \(^6,^7\). An investigational *S. aureus* vaccine has been under development for the prevention of invasive *S. aureus* disease in patients undergoing orthopedic surgery, including deep or organ/space surgical site infections and bloodstream infections \(^8\). The investigational vaccine targets highly conserved virulence factors expressed early during infection, and has been evaluated in clinical studies, initially as a 3-antigen *S. aureus* vaccine (SA3Ag) \(^9,^10\), and then as a 4-antigen *S. aureus* vaccine (SA4Ag) \(^11,^12\). SA3Ag contains capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) conjugated to CRM\(_{197}\), and a recombinant surface protein clumping factor A (rmClfA) that is mutated to remove the ability to bind fibrinogen. In addition to the antigens in SA3Ag, SA4Ag includes the lipoprotein manganese transporter protein C (MntC), which is expressed as a recombinant non-lipidated protein (rMntC, also known as rP305A) \(^11,^12\). These antigens were selected based on several criteria described by Anderson and coworkers \(^13\). All four antigens are expressed during human infection \(^14\) and were protective in preclinical models that mimic human disease \(^15\). Bacteria express CPs to help them evade innate immune responses. While CPs are not naturally immunogenic, immunogenicity is improved when conjugated to a carrier protein, and vaccination with CP conjugates can induce antibodies capable of killing bacteria \(^16\). *S. aureus* uses ClfA to bind to human fibrinogen and this is an early step in the organism establishing persistent infection. Humans do not naturally express antibodies that prevent ClfA binding; however, the ClfA antigen was designed to induce antibodies that can
block this virulence mechanism \cite{17}. MntC was discovered during a proteomics screen of antigens that are expressed \textit{in vivo} \cite{18} and is not expressed in artificial media. MntC facilitates manganese acquisition and has a role in helping \textit{S. aureus} survive phagocytosis \cite{19,20}. By targeting MntC, antibodies prevent \textit{S. aureus} from acquiring this important element and evading the host defence \cite{21}.

Two studies of SA4Ag evaluated the immunogenicity and overall safety of a single vaccination up to 12 months post-vaccination \cite{11,12}. Both studies found that SA4Ag was well tolerated, was not associated with vaccine-related serious adverse events, and elicited robust functional immune responses after a single vaccination, with rapidly-induced, high levels of bacteria-killing antibodies and sustained immune responses observed at 12 months post-vaccination. To evaluate the duration of immune responses, a serological extension study (Study B3451014) through approximately 36 months post-vaccination was conducted. While the SA4Ag vaccine development program is currently under evaluation due to meeting futility criteria at a pre-specified interim efficacy assessment of a phase 2b clinical trial \cite{22}, antibody persistence data may inform future studies of \textit{S. aureus} vaccines.

**METHODS**

**Study Population**

The study was conducted at 12 study sites in the United States from January 2014 to April 2016 and included subjects who were enrolled in previous studies (NCT01643941 and NCT01364571) evaluating SA4Ag \cite{11,12} and had blood collected at both the baseline (pre-vaccination) and month 12 post-vaccination time points. Subjects in the current extension study were asked to donate additional blood samples at approximately 24 months (Visit 1) and 36 months (Visit 2) post-vaccination. All subjects who received SA4Ag or placebo in the primary study were considered for participation; however, the reasons why subjects declined to participate in this extension study were not collected. Due to the timing
of the initiation of the extension study, in some subjects, the timing of the first sample was as late as 30 months after vaccination while others only had collection of the 36-month post-vaccination specimen.

Subjects were excluded from taking part in the extension study after participation in the primary SA4Ag vaccine trials if they had: (1) participated in clinical studies investigating the use of immune modulators and/or non-Pfizer S. aureus/Candida vaccine studies; (2) developed a known or suspected defect of the immune system, including those receiving chronic, systemic corticosteroid therapies, or those receiving immunosuppressive therapy; (3) received blood products or immunoglobulins (including monoclonal antibodies) within 6 months before a study visit; (4) developed a bleeding diathesis or condition associated with prolonged bleeding time that could affect routine blood draw; or (5) developed a severe physical or mental condition or laboratory abnormality that the investigator deemed would adversely affect the study participation, making the subject inappropriate for study entry.

The primary immunogenicity population was the evaluable immunogenicity population, and included all subjects who were eligible, had blood drawn within the protocol-specified time frame, had valid and determinate assay results for the proposed analysis, and had no major protocol deviations. Subjects who had a confirmed S. aureus infection since completion of the primary study were excluded from the evaluable immunogenicity population.

The study protocol was approved by the institutional review board or the independent ethics committee for each of the study sites. The study was conducted in compliance with original or derivative ethical principles from the Declaration of Helsinki and in compliance with all guidelines of the International Council on Harmonization (ICH) Good Clinical Practice (GCP). In addition, all local regulatory requirements were followed. Written informed consent was obtained from each subject before enrollment in the study and before performance of any study-related procedures.
Study Vaccine

No vaccines were administered in this extension study. Subjects were vaccinated in the 2 primary vaccination studies\textsuperscript{11,12} with a single intramuscular dose of 1 of the 3 formulations of SA4Ag, with placebo, or with SA3Ag – a formulation without rMntC used only in the study for subjects 65–85 years of age\textsuperscript{12}. The 3 formulations of SA4Ag and the single formulation of SA3Ag included fixed-dose CP5-CRM\textsubscript{197}, CP8-CRM\textsubscript{197}, and rMntC\textsubscript{A} (30 \( \mu g \), 30 \( \mu g \), and 60 \( \mu g \), respectively). SA4Ag also included rMntC at 20 \( \mu g \) (low-dose SA4Ag), 60 \( \mu g \) (mid-dose SA4Ag), or 200 \( \mu g \) (high-dose SA4Ag).

Study Assessments

Immunogenicity

The primary studies were unblinded as planned on completion; thus, in this extension study, the subjects, investigators, and study site staff were unblinded. However, immunogenicity assays were performed by laboratory staff unaware of the study vaccine received by the subject.

Immunogenicity was assessed at baseline (pre-vaccination), day 29, month 12, month 24/30, and month 36 post-vaccination. Serum samples of baseline, day 29, and month 12 time points were collected from the primary studies but were reassessed using the current validated assays to allow evaluation of the immune response kinetics from vaccination through month 36.

Five assays were performed at each blood sampling time point to assess the immune response to the vaccine\textsuperscript{11,12}. Functional immune responses (antibody responses that facilitate the killing of \textit{S. aureus} or neutralize \textit{S. aureus} virulence mechanisms) were assessed using validated opsonophagocytic activity (OPA) killing assays using CP5- or CP8-expressing \textit{S. aureus} strains\textsuperscript{16}, and using the qualified fibrinogen-binding inhibition (FBI)
assay 17 for ClfA. Responses to ClfA and rMntC were measured using a validated multiplex competitive Luminex® immunoassay (cLIA) 14.

Qualified OPAs were used to measure functional antibodies specific for CP5- or CP8-expressing strains of S. aureus 18 in human sera. Human test serum was serially diluted two-fold and added to microtiter assay plates. Live target bacterial strains (CP5 or CP8) were added to the wells and the plates were shaken at 4°C for 30 minutes. Differentiated HL-60 cells (phagocytes) and baby rabbit serum (complement source) were added to the wells, and the plates were shaken at 37°C for 60 minutes. Following these incubations, an aliquot of assay reaction from each well was transferred to filter plates to enumerate surviving bacteria. The filter-plates were incubated overnight at 37°C to allow bacterial colonies to form. Following incubation, the plates were fixed and the colonies were stained with Coomassie blue stain. Colonies were imaged and counted using CTL ImmunoSpot readers. Raw colony counts were used to plot kill curves and calculate OPA titers. The OPA titer is defined as the reciprocal dilution that results in a 50% reduction in bacterial count compared with control wells without test serum. The OPA titer is interpolated from the two dilutions that encompass this 50% killing cut-off. The reported OPA titer is the geometric mean of two replicate OPA titers.

A qualified FBI Assay was used to measure functional clumping factor A (ClfA)-specific immunoglobulin in human sera17. The FBI assay measures the ability of anti-ClfA antibodies to prevent the binding of live ClfA-expressing S. aureus isolates to plate-immobilized human fibrinogen. Briefly, two-fold serial dilutions of human test serum were incubated with a fixed amount of live bacteria with shaking at 37°C for 30-60 minutes. The opsonized bacteria were then added to plates pre-coated with human fibrinogen and incubated at 37°C for 60 minutes. After subsequent washing steps, the amount of live bacteria bound to the immobilized fibrinogen was detected by incubation with BacTiter-Glo detection reagent at 37°C for 15 minutes. Following incubation, assay plates were read using a luminometer. The FBI assay titer is defined as the reciprocal dilution that results in 75%
inhibition of bacterial binding compared with the average binding observed in control wells without test serum.

As noted above, a qualified cLIA was used to measure antibody responses to ClfA\textsuperscript{17} and rMntC\textsuperscript{21} in human serum. Briefly, antigen-coated microspheres were incubated overnight with appropriately diluted serum samples, controls and reference standard serum. A mixture of phycoerythrin-labeled ClfA and r305 specific mouse monoclonal antibodies were then added to the microsphere/serum mixture and after a two-hour incubation, the unbound components were washed off using a magnetic bead washer. The magnitude of the fluorescence signal allows for measurement of the antibody bound to the antigen-coated microspheres by the Bio-Plex reader. Raw data are expressed as median fluorescence intensities and read against a reference standard.

**Safety**

Adverse events (AEs) occurring within 48 hours of the immunogenicity blood draw were recorded. Serious AEs (SAEs) considered by the investigator to be possibly vaccine-related were reported as a part of follow-up from the primary studies.

**Immunogenicity Endpoints**

At each time point, the following analyses were performed: (1) proportions of subjects achieving titers greater than or equal to predefined threshold criteria that were considered potentially biologically relevant, based on prior clinical studies and animal models, as previously described \textsuperscript{11,12} (for the OPA assays, the thresholds were \(\geq 1000\) for CP5-CRM\textsubscript{197} and \(\geq 2000\) for CP8-CRM\textsubscript{197}; for \(rmClfA\), the threshold was greater than or equal to the lower limit of quantitation [LLOQ, 121] based on the FBI assay; for rMntC, it was greater than or equal to the LLOQ [128.00] based on the cLIA); (2) geometric mean titers (GMTs) for functional antibody assays (including OPA for CP5/CP8 and FBI for ClfA) and antigen-
specific cLIA titers (for ClfA and rMntC); and (3) geometric mean fold rises (GMFRs) from baseline (pre-vaccination) for each antigen (measured by OPA, FBI, or cLIA).

**Statistical Analysis**

This study did not test a hypothesis; instead, descriptive statistics were compiled and analyzed. For each time point in each assay, GMTs were calculated by log transforming assay values, calculating means, then exponentially converting the means to return them to the original scale. For values below the LLOQ, the value used was half the LLOQ of the specific assay. The 95% confidence intervals (CIs) were determined through back transformations of the confidence limits computed for the mean of the logarithmically transformed assay data based on Student’s t-distribution.

**RESULTS**

**Participants**

Four hundred and forty (440) of the 737 subjects vaccinated in the primary studies were enrolled (Table 1). Of the 454 subjects in the initial study of 18–64-year-olds 11, 255 (56%) participated in the extension study, and 185 of the 283 (65%) subjects aged 65–85 years also participated 12.

Thirty-six (36) of the 420 subjects who enrolled at Visit 1 withdrew from the study before Visit 2, and 20 subjects who missed Visit 1 were enrolled at Visit 2. None of the subjects withdrew for safety-related reasons.

Demographics of the older cohort (65–85-year-olds) were comparable to the primary study 12; however, subjects from the younger cohort (18–64-year-olds) were slightly older, with more female and more white subjects compared with the primary study population 11. In
this follow-up study, more female than male subjects were enrolled (61.6% and 51.9% in the younger and older cohorts, respectively), and the majority of subjects were white (83.5% and 91.9% in the younger and older cohorts, respectively). Mean age at vaccination was 46.3 years in the total younger cohort and 70.7 years in the total older cohort; mean age in each cohort was similar across active vaccine and placebo groups. Mean age at enrollment was 48.5 years in the total younger cohort and 72.7 years in the total older cohort; mean age in each cohort was similar across active vaccine and placebo groups (Supplementary Table 1).

Immunogenicity

Overall, 94.9% (242/255) and 96.2% (178/185) of subjects were included in the evaluable population in the younger and older cohorts, respectively. In all SA4Ag groups, rapid and substantial increases in OPA, FBI, and cLIA GMTs for all 4 antigens were observed at day 29 post-vaccination, with dose-dependent cLIA GMTs observed for rMntC \(^{11,12}\). In comparison to the gradual declines of OPA, FBI, and cLIA GMTs for all 4 antigens observed through month 12 post-vaccination \(^{11,12}\), a lower rate of decline was observed for all 4 antigens from month 12 to month 36 (Figure 1), indicating sustained immune responses. While GMTs for rMntC declined from month 12 to near baseline and placebo levels at month 36, they remained higher at month 36 than at baseline in both age cohorts in all SA4Ag groups (Figure 1) as the lower bounds of the GMFRs were above 1 for all subjects: 1.2–1.5 in the younger cohort and 1.1–1.4 in the older cohort (data not shown).

In the high-dose SA4Ag group, the CP5, CP8, and ClfA GMTs at 36 months post-vaccination were well above baseline (Table 2) with GMFRs from baseline to month 36 ranging from 2.7 to 8.1 (Table 3). GMFRs for CP5 (OPA), CP8 (OPA), ClfA (FBI), and ClfA (cLIA) were 8.1, 4.5, 3.9, and 4.4 in the younger cohort, respectively; these were 6.3, 4.3, 2.7, and 4.0 in the older cohort, respectively (Table 3). For rMntC, the GMTs at 36 months post-vaccination remained higher than at baseline in both age cohorts (Table 2) with GMFRs
from baseline to month 36 of 1.8 in the younger cohort (95% CI: 1.5–2.1) and 1.5 in the older cohort (95% CI: 1.2–1.8) (Table 3).

In the high-dose SA4Ag group, the proportions of subjects achieving predefined OPA threshold functional response criteria for CP5 and CP8 at month 36 ranged from 81.8% to 97.9% in both age cohorts (compared with 2.9%–35.3% of placebo recipients). In the younger cohort, the proportions were 97.9% and 87.5%, respectively; in the older cohort the proportions were 88.2% and 81.8%, respectively (Figure 2). The proportion of subjects achieving predefined FBI threshold functional response criteria for ClIA at month 36 was 73.5% in the younger cohort, and was 50.0% in the older cohort (compared with 2.0% and 0.0% of placebo recipients in those cohorts, respectively) (Figure 2). Nearly all subjects (>90%) achieved the predefined cLIA threshold for rMntC at all time points from baseline to month 36 in both cohorts including placebo recipients (Figure 2). The threshold for cLIA results was set at the LLOQ of the assay, which was determined based on assay performance (assay linearity and precision); this threshold is relatively low and thus the immune responses elicited by rMntC, as shown by substantial rises in GMTs and GMFRs (Tables 2 and 3), were not able to be demonstrated by the threshold analysis, due to the high proportions of participants with assay results above threshold at baseline.

Safety
No AEs were reported in the 48 hours following each blood draw. No vaccine-related SAEs were reported up to month 36 post-vaccination.

DISCUSSION
The current study demonstrated that antibody levels at 3 years after single-dose vaccination with SA4Ag remained above pre-vaccination levels in adults 18 to 85 years of age. The robust functional immune responses elicited against key *S. aureus* virulence mechanisms were demonstrated by OPA killing assays (>80% of subjects achieved predefined OPA titer
thresholds at 36 months), and functional antibody responses to ClfA above the FBI predefined threshold in most subjects. Responses to the fourth antigen (rP305A or rMntC) had substantially declined at 36 months; however, the GMTs remained above baseline level in both age groups.

Increased age may impact vaccine immunogenicity and efficacy; for influenza vaccines, this has led to the development of high-dose influenza vaccine formulations to increase vaccine efficacy in the elderly. However, immune responses to vaccines are not necessarily impaired in older age, as demonstrated by durable immune responses in the elderly in this study and in the primary SA4Ag study by Creech et al. Similarly, protective responses of licensed vaccines in older age have been reported. For example, large phase 3 studies of a herpes zoster vaccine have shown comparable efficacy against herpes zoster across 3 age groups (50–59, 60–69, and ≥70 years of age), and no difference in vaccine efficacy in participants 70–79 (90.0% efficacy) and ≥80 years of age (89.1% efficacy).

There are many potential indications for an S. aureus vaccine, given the spectrum of disease and various populations at risk. However, elective surgery represents a priority population due to the relatively high incidence of disease, a well-defined risk period (the time of surgery), and the opportunity to vaccinate prior to the period of risk. SA4Ag efficacy has been undergoing efficacy assessment in a randomized, placebo-controlled study among patients undergoing elective instrumented spinal fusion surgery (ClinicalTrials.gov identifier NCT02388165). Recently, this clinical trial ceased enrollment due to meeting its pre-specified futility criteria at an interim efficacy analysis in December 2018, however there were no safety concerns. Investigation is currently underway to understand these results in the elective spinal surgical population evaluated. Other investigational S. aureus vaccines are under development, including other candidates that share antigens with SA4Ag (eg, CP5, CP8, and ClfA). The antibody persistence results we present in this healthy population are therefore relevant to the S. aureus vaccine development field. Given the substantial burden of healthcare- and community-associated
disease, there remains an unmet medical need to develop a vaccine to prevent *S. aureus* disease. Further research into humoral and cell-mediated immune responses to *S. aureus* antigens is critical to support ongoing vaccine development.

**Financial support.** This study was sponsored by Pfizer Inc.

**Acknowledgments and Disclosures**

Editorial support was provided by Thomas Gegeny, PhD and Chu Kong Liew, PhD of Engage Scientific Solutions and was funded by Pfizer Inc. We thank Pfizer colleagues from Vaccine Clinical Research & Development, High-Throughput Clinical Testing, Clinical Development Operations, Pharmaceutical Sciences, Vaccine Regulatory and Project Management, clinical center collaborators, and clinical trial participants.

**Potential conflicts of interest.** C.B.C., R.W.F., R.F., and M.K.K. received grant support from Pfizer to conduct the study. All other authors were employees of Pfizer.

**Data availability.** Upon request, and subject to certain criteria, conditions and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (ie, development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.
References

1. Diekema DJ, Pfaffer MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clin Infect Dis.* **2001**;32 Suppl 2:S114-132.

2. Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. *J Hosp Infect.* **2008**;70 Suppl 2:3-10.

3. Baker AW, Dicks KV, Durkin MJ, et al. Epidemiology of surgical site infection in a community hospital network. *Infect Control Hosp Epidemiol.* **2016**;37(5):519-526.

4. Campbell RS, Emons MF, Mardekian J, Girgenti D, Gaffney M, Yu H. Adverse Clinical Outcomes and Resource Utilization Associated with Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Infections after Elective Surgery. *Surg Infect (Larchmt).* **2015**;16(5):543-552.

5. Mohamed N, Wang MY, Le Huec JC, et al. Vaccine development to prevent Staphylococcus aureus surgical-site infections. *Br J Surg.* **2017**;104(2):e41-e54.

6. Lowy FD. Staphylococcus aureus infections. *N Engl J Med.* **1998**;339(8):520-532.

7. Anderson DJ, Kaye KS. Staphylococcal surgical site infections. *Infect Dis Clin North Am.* **2009**;23(1):53-72.

8. Gurtman A, Begier E, Mohamed N, et al. The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery. *Hum Vaccin Immunother.* **2019**;15(2):358-370.

9. Nissen M, Marshall H, Richmond P, et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. *Vaccine.* **2015**;33(15):1846-1854.

10. Marshall H, Nissen M, Richmond P, et al. Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. *J Infect.* **2016**;73(5):437-454.
11. Frenck RW, Jr., Creech CB, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. *Vaccine.* 2017;35(2):375-384.

12. Creech CB, Frenck RW, Jr., Sheldon EA, et al. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. *Vaccine.* 2017;35(2):385-394.

13. Anderson AS, Miller AA, Donald RG, et al. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. *Hum Vaccin Immunother.* 2012;8(11):1585-1594.

14. Rozemeijer W, Fink P, Rojas E, et al. Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease. *PLoS One.* 2015;10(2):e0116945.

15. Scully IL, Liberator PA, Jansen KU, Anderson AS. Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine. *Front Immunol.* 2014;5:109.

16. Nanra JS, Buitrago SM, Crawford S, et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. *Hum Vaccin Immunother.* 2013;9(3):480-487.

17. Hawkins J, Kodali S, Matsuka YV, et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. *Clin Vaccine Immunol.* 2012;19(10):1641-1650.

18. Anderson AS, Scully IL, Timofeyeva Y, et al. Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis. *J Infect Dis.* 2012;205(11):1688-1696.
19. Handke LD, Gribenko AV, Timofeyeva Y, Scully IL, Anderson AS. MntC-Dependent Manganese Transport Is Essential for Staphylococcus aureus Oxidative Stress Resistance and Virulence. *mSphere*. **2018**;3(4).

20. Handke LD, Hawkins JC, Miller AA, Jansen KU, Anderson AS. Regulation of Staphylococcus aureus MntC expression and its role in response to oxidative stress. *PLoS One*. **2013**;8(10):e77874.

21. Gribenko AV, Parris K, Mosyak L, et al. High Resolution Mapping of Bactericidal Monoclonal Antibody Binding Epitopes on Staphylococcus aureus Antigen MntC. *PLoS Pathog*. **2016**;12(9):e1005908.

22. Pfizer Inc. Independent data monitoring committee recommends discontinuation of the Phase 2B STRIVE clinical trial of *Staphylococcus aureus* vaccine following planned interim analysis. 2018. Available from: https://investors.pfizer.com/investor-news/press-release-details/2018/Independent-Data-Monitoring-Committee-Recommends-Discontinuation-of-the-Phase-2b-STRIVE-Clinical-Trial-of-Staphylococcus-aureus-Vaccine-Following-Planned-Interim-Analysis/default.aspx. Accessed 7 February 2019.

23. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. *Lancet Infect Dis*. **2015**;15(3):293-300.

24. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. *N Engl J Med*. **2015**;372(22):2087-2096.

25. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. *N Engl J Med*. **2016**;375(11):1019-1032.

26. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev*. **2015**;28(3):603-661.
27. World Health Organization. *Global Guidelines for the Prevention of Surgical Site Infection* [ePub ahead of print]. doi. Geneva: World Health Organization; 2016.

28. Levy J, Licini L, Haelterman E, et al. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial. *Hum Vaccin Immunother.* 2015;11(3):620-631.
Table 1. Disposition of Enrolled Subjects

| Vaccine Groups | Low-Dose | High-Dose | Total |
|----------------|----------|-----------|-------|
| Placebo        | n        | n         | n/A   |
| SA4Ag          | n        | n         | n     |
| Mid-Dose SA4Ag | n        | n         | n     |
| SA4Ag          | n        | n         | n     |
| SA3Ag<sup>b</sup> | n   | n         | N/A   |

| Younger Cohort: Subjects 18–64 Years of Age |
|---------------------------------------------|
| Enrolled at Visit 1 (Month 24/30)<sup>c</sup> | 66 | 63 | 69 | 57 | N/A | 255 |
| Withdrawn before Visit 2 (Month 36)         | 12 | 6  | 8  | 4  | –   | 30  |
| Lost to Follow-up                           | 6  | 5  | 5  | 1  | –   | 17  |
| No Longer Meets Entrance Criteria           | 0  | 0  | 1  | 2  | –   | 3   |
| No Longer Willing to Participate in Study   | 5  | 0  | 1  | 1  | –   | 7   |
| Other                                       | 1  | 1  | 0  | –  | –   | 3   |
| Enrolled at Visit 2 (Month 36)              | 54 | 57 | 61 | 53 | –   | 225 |
| Completed Visit 2 (Month 36)                | 54 | 57 | 61 | 53 | –   | 225 |

| Older Cohort: Subjects 65–85 Years of Age |
|-------------------------------------------|
| Enrolled at Visit 1 (Month 24)            | 38 | 43 | 33 | 37 | 34  | 183 |
| Withdrawn before Visit 2 (Month 36)       | 2  | 1  | 1  | 0  | 2   | 6   |
| Lost to Follow-up                         | 1  | 0  | 0  | 0  | 1   | 2   |
| No Longer Meets Entrance Criteria         | 0  | 1  | 0  | 0  | 0   | 1   |
| Vaccine Groups<sup>a</sup> | Low-Dose | High-Dose |
|--------------------------|----------|----------|
|                         | Placebo | SA4Ag | Mid-Dose SA4Ag | SA4Ag | SA3Ag<sup>b</sup> | Total |
| n                       | n       | n      | n             | n     | n                | n     |
| Other                    | 1       | 0      | 1             | 0     | 1                | 3     |
| Enrolled at Visit 2 (Month 36) | 1       | 0      | 1             | 0     | 0                | 2     |
| Completed Visit 2 (Month 36) | 36      | 42     | 32            | 37    | 32               | 179   |

Abbreviations: CP5, capsular polysaccharide serotype 5; CP8, capsular polysaccharide serotype 8; N/A, not applicable; rMClfA, recombinant mutant clumping factor A; rMntC, recombinant manganese transporter protein C; SA3Ag, *Staphylococcus aureus* 3-antigen vaccine; SA4Ag, *S. aureus* 4-antigen vaccine.

<sup>a</sup>Vaccine groups labeled low-dose, mid-dose, and high-dose SA4Ag refer only to differences in rMntC dose levels (20 μg, 60 μg, and 200 μg, respectively). CP5-CRM<sub>197</sub>, CP8-CRM<sub>197</sub>, and rMClfA dose levels (30 μg, 30 μg, and 60 μg, respectively) are the same in each SA4Ag dose level, and in SA3Ag.

<sup>b</sup>For subjects 65–85 years of age only.

<sup>c</sup>43 subjects were enrolled at month 30.
Table 2. *Staphylococcus aureus* Antigen-Specific GMTs in the Evaluable Immunogenicity Population

| Antigen | Placebo | High-Dose SA4Ag<sup>a</sup> |
|---------|---------|-----------------------------|
|         | Baseline<sup>c</sup> | Day 29<sup>d</sup> | Month 12<sup>d</sup> | Month 36<sup>d</sup> | Baseline<sup>c</sup> | Day 29<sup>d</sup> | Month 12<sup>d</sup> | Month 36<sup>d</sup> |
| Group<sup>b</sup> | (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) |
| CP5<sup>f</sup> | | | | | | | | |
| 18–64 | 440.0 | 469.4 | 443.5 | 423.7 | 671.8 | 45715.6 | 9408.1 | 5242.9 |
| | (324.3–597.0) | (346.8–635.2) | (337.5–582.8) | (295.6–607.3) | (466.4–967.6) | (37231.4–56133.1) | (7418.7–11931.0) | (4033.3–6815.4) |
| 65–85 | 266.7 | 303.4 | 253.6 | 210.1 | 581.7 | 38912.6 | 7144.5 | 3661.5 |
| | (175.9–404.3) | (210.0–438.4) | (168.7–381.3) | (148.0–298.2) | (366.7–922.8) | (27278.4–55508.9) | (5227.0–9765.6) | (2514.5–5331.8) |
| CP8<sup>f</sup> | | | | | | | | |
| 18–64 | 837.2 | 880.9 | 823.3 | 878.2 | 1367.2 | 37306.1 | 9127.7 | 6313.5 |
| | (592.5–1182.9) | (622.5–1246.5) | (586.7–1155.1) | (588.6–1310.1) | (844.7–2213.1) | (27170.8–51222.0) | (6375.6–13067.7) | (4376.5–9107.6) |
| 65–85 | 769.1 | 825.7 | 914.9 | 663.6 | 1255.5 | 38609.3 | 9064.3 | 5195.9 |
| | (433.3–1365.3) | (474.1–1438.2) | (512.5–1633.3) | (399.7–1101.7) | (711.1–2216.7) | (25389.7–58712.0) | (5690.3–14438.8) | (3296.7–8189.1) |
| CfIA<sup>i</sup> | | | | | | | | |
| 18–64 | 62.8 | 63.7 | 61.2 | 61.9 | 60.5 | 1322.7 | 396.9 | 238.8 |
| | (60.2–65.5) | (60.5–67.0) | (59.8–62.6) | (59.1–64.8) | (NE–NE) | (899.7–1944.5) | (278.0–566.7) | (174.8–326.3) |
| 65–85 | 61.7 | 60.5 | 60.5 | 60.5 | 60.5 | 1756.3 | 395.7 | 162.3 |
| | (59.3–64.2) | (NE–NE) | (NE–NE) | (NE–NE) | (NE–NE) | (1172.4–2630.8) | (271.7–576.5) | (108.0–243.9) |
Abbreviations: CI, confidence interval; ClfA, surface protein clumping factor A; cLIA, competitive Luminex® immunoassay; CP5, capsular polysaccharide serotype 5; CP8, capsular polysaccharide serotype 8; FBI, fibrinogen-binding inhibition; GMT, geometric mean titer; NE, not estimable; OPA, opsonophagocytic activity; rMntC, recombinant manganese transporter protein C; SA4Ag, Staphylococcus aureus 4-antigen vaccine.

The evaluable immunogenicity population included all subjects who were eligible, had no confirmed S. aureus infection since completion of the primary study, had blood drawn within the protocol-specified time frame, had valid and determinate assay results for the proposed analysis, and had no major protocol deviations.

Age group in years.

Pre-vaccination.

Post-vaccination.

High-dose SA4Ag included CP5-CRM$_{197}$ 30 μg, CP8-CRM$_{197}$ 30 μg, rClfA 60 μg, and rMntC 200 μg.

Determined via OPA assay.

|    | 18–64 | 221.8 | 194.7 | 248.2 | 193.4 | 4841.0 | 1359.9 | 867.3 |
|----|-------|-------|-------|-------|-------|--------|--------|-------|
|    | (165.2–239.7) | (165.6–242.7) | (156.7–234.2) | (159.7–274.8) | (322.8–7258.3) | (963.7–1918.9) | (653.7–1150.1) | |
| 65–85 | 187.3 | 171.9 | 153.9 | 206.8 | 156.7 | 581.0 | 1012.2 | 621.6 |
|    | (160.7–218.2) | (151.8–194.6) | (133.9–176.9) | (184.9–231.4) | (129.2–190.0) | (3596.7–9388.6) | (660.4–1552.2) | (432.1–894.2) |
| rMntC$^c$ | 358.6 | 375.5 | 322.8 | 374.6 | 367.6 | 3244.0 | 817.4 | 658.9 |
|    | (303.2–424.3) | (322.8–436.8) | (270.2–385.7) | (330.4–424.6) | (308.2–438.4) | (2272.6–4630.6) | (609.9–1095.5) | (535.9–810.2) |
| 65–85 | 286.8 | 292.2 | 259.2 | 354.8 | 288.0 | 1581.9 | 435.2 | 427.7 |
|    | (240.7–341.7) | (249.8–341.9) | (226.0–297.2) | (317.8–396.2) | (239.1–346.8) | (1068.5–2342.1) | (354.5–534.2) | (359.5–508.7) |
\textsuperscript{9}Determined via FBI assay.

\textsuperscript{h}Determined via cLIA.
Table 3. *Staphylococcus aureus* Antigen-Specific Responses in the Evaluable Immunogenicity Population: GMFR from Baseline at Month 36

| Antigen | Age Group (years) | Placebo GMFR (95%CI) | High-Dose SA4Ag<sup>a</sup> GMFR (95% CI) |
|---------|------------------|----------------------|---------------------------------|
| CP5<sup>b</sup> | 18–64 | 1.0 (0.8–1.3) | 8.1 (6.0–10.8) |
| | 65–85 | 0.8 (0.6–0.9) | 6.3 (4.0–9.8) |
| CP8<sup>b</sup> | 18–64 | 1.0 (0.8–1.2) | 4.5 (3.2–6.4) |
| | 65–85 | 0.8 (0.6–1.0) | 4.3 (2.5–7.3) |
| ClfA<sup>c</sup> | 18–64 | 1.0 (1.0–1.1) | 3.9 (2.8–5.3) |
| | 65–85 | 1.0 (0.9–1.0) | 2.7 (1.8–4.0) |
| ClfA<sup>d</sup> | 18–64 | 1.3 (1.0–1.6) | 4.4 (3.1–6.3) |
| | 65–85 | 1.1 (1.0–1.3) | 4.0 (2.9–5.4) |
| rMntC<sup>d</sup> | 18–64 | 1.0 (0.9–1.3) | 1.8 (1.5–2.1) |
| | 65–85 | 1.3 (1.1–1.5) | 1.5 (1.2–1.8) |

Abbreviations: CI, confidence interval; ClfA, surface protein clumping factor A; cLIA, competitive Luminex® immunoassay; CP5, capsular polysaccharide serotype 5; CP8, capsular polysaccharide serotype 8; FBI, fibrinogen-binding inhibition; GMFR, geometric mean fold rise; OPA, opsonophagocytic activity; rMntC, recombinant manganese transporter protein C; SA4Ag, *Staphylococcus aureus* 4-antigen vaccine.

<sup>a</sup>High-dose SA4Ag included CP5-CRM<sub>197</sub> 30 μg, CP8-CRM<sub>197</sub> 30 μg, rmClfA 60 μg, and rMntC 200 μg.

<sup>b</sup>Determined via OPA assay.

<sup>c</sup>Determined via FBI assay.

<sup>d</sup>Determined via cLIA.
Figure 1. Immunogenicity results in the evaluable immunogenicity population.\textsuperscript{a} (A) The younger cohort (18–64 years of age). (B) The older cohort (65–85 years of age).

Abbreviations: ClfA, surface protein clumping factor A; cLIA, competitive Luminex® immunoassay; CP5, capsular polysaccharide serotype 5; CP8, capsular polysaccharide serotype 8; FBI, fibrinogen-binding inhibition; OPA, opsonophagocytic activity; rMntC, recombinant manganese transporter protein C; SA3Ag, \textit{Staphylococcus aureus} 3-antigen vaccine; SA4Ag, \textit{S. aureus} 4-antigen vaccine.

\textsuperscript{a}The evaluable immunogenicity population included all subjects who were eligible, had no confirmed \textit{S. aureus} infection since completion of the primary study, had blood drawn within the protocol-specified time frame, had valid and determinate assay results for the proposed analysis, and had no major protocol deviations.

\textsuperscript{b}Vaccine groups labeled low-dose, mid-dose, and high-dose SA4Ag refer only to differences in rMntC levels (20 μg, 60 μg, and 200 μg, respectively). CP5-CRM\textsubscript{197}, CP8-CRM\textsubscript{197}, and \textit{rMntClfA} levels (30 μg, 30 μg, and 60 μg, respectively) are the same in each SA4Ag dose level, and in SA3Ag.

Figure 2. Percentage of subjects achieving predefined antibody thresholds at month 36 post-vaccination in the evaluable immunogenicity population.\textsuperscript{a}

Error bars indicate 95% confidence intervals for each value. Younger cohort: 18–64 years of age; older cohort: 65–85 years of age.

Abbreviations: ClfA, surface protein clumping factor A; cLIA, competitive Luminex® immunoassay; CP5, capsular polysaccharide serotype 5; CP8, capsular polysaccharide serotype 8; FBI, fibrinogen-binding inhibition; OPA, opsonophagocytic activity; rMntC,
recombinant manganese transporter protein C; SA3Ag, *Staphylococcus aureus* 3-antigen vaccine; SA4Ag, *S. aureus* 4-antigen vaccine.

The evaluable immunogenicity population included all subjects who were eligible, had no confirmed *S. aureus* infection since completion of the primary study, had blood drawn within the protocol-specified time frame, had valid and determinate assay results for the proposed analysis, and had no major protocol deviations.

Vaccine groups labeled low-dose, mid-dose, and high-dose SA4Ag refer only to differences in rMntC levels (20 µg, 60 µg, and 200 µg, respectively). CP5-CRM197, CP8-CRM197, and rmClfA levels (30 µg, 30 µg, and 60 µg, respectively) are the same in each SA4Ag dose level, and in SA3Ag.

For rMntC, the threshold for cLIA results was set at the lower limit of quantitation of the assay, which was determined based on assay linearity and precision; this threshold is relatively low and thus the immune responses elicited by rMntC were not able to be detected due to the high proportions of participants with assay results above threshold.
Figure 1. Immunogenicity results in the evaluable immunogenicity population.\textsuperscript{a}
Figure 2. Percentage of subjects achieving predefined antibody thresholds at month 36 post-vaccination in the evaluable immunogenicity population.\(^a\)